Related Articles
Therapeutic effects of the dipeptidyl peptidase-IV inhibitor, sitagliptin, on non-alcoholic steatohepatitis in FLS-ob/ob male mice
Ezetimibe prevents the development of non‑alcoholic fatty liver disease induced by high‑fat diet in C57BL/6J mice
Establishment of a novel non‑alcoholic fatty liver disease model using cholesterol‑fed rabbits with reference to the potential role of endoplasmic reticulum stress
Alogliptin alleviates hepatic steatosis in a mouse model of nonalcoholic fatty liver disease by promoting CPT1a expression via Thr172 phosphorylation of AMPKα in the liver
Sitagliptin reduces insulin resistance and improves rat liver steatosis via the SIRT1/AMPKα pathway